In summary, the low toxicity of B7-H6-targeted therapy is primarily attributable to its tumor-specific expression and precise targeting mechanism, thus rendering it a promising low-toxicity immunotherapy strategy. The gene discussed is NCR3LG1; the disease is neoplasm.